Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Clinical trial NCT05631795 · COMPLETED
Trial details
- NCT number
- NCT05631795
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-09
- Primary completion
- 2025-06-12
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.